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BioID screening of biotinylation sites using the avidin-like
protein Tamavidin 2-REV identifies global interactors of
stimulator of interferon genes (STING)
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Stimulator of interferon genes (STING) mediates cytosolic
DNA-induced innate immune signaling via membrane traffick-
ing. The global identification of proteins that spatiotemporally
interact with STING will provide a better understanding of its
traffickingmechanisms and of STING signaling pathways. Prox-
imity-dependent biotin identification (BioID) is a powerful
technology to identify physiologically relevant protein-protein
interactions in living cells. However, biotinylated peptides are
rarely detected in the conventional BioID method, which uses
streptavidin beads to pull down biotinylated proteins, because the
biotin-streptavidin interaction is too strong. As a result, only non-
biotinylated peptides are identified, which cannot be distin-
guished from peptides of nonspecifically pull-downed proteins.
Here, we developed a simplemethod to efficiently and specifically
enrich biotinylated peptides using Tamavidin 2-REV, an engi-
neered avidin-like protein with reversible biotin-binding capabil-
ity. Using RAW264.7 macrophages stably expressing TurboID-
fused STING, we identified and quantified >4,000 biotinylated
peptides of STING-proximal proteins. Various endoplasmic retic-
ulum-associated proteins were biotinylated in unstimulated cells,
and STING activation caused biotinylation of many proteins
located in the Golgi and endosomes. These proteins included
those known to interact with activated STING, such as TANK-
binding kinase 1 (TBK1), several palmitoyl transferases, and p62/
sequestosome 1 (SQSTM1). Furthermore, interferon-induced
transmembrane protein 3 (IFITM3), an endolysosome-localized
antiviral protein, bound to STING at the late activation stage.
These dynamic interaction profiles will provide detailed insights
into STING signaling; we propose that our approach using Tama-
vidin 2-REV would be useful for BioID-based and other biotinyla-
tion-based peptide identificationmethods.
The presence of pathogenic or self-DNA in the cytosol is a
danger signal that triggers the host innate immune system and
leads to the production of cyclic GMP-AMP (cGAMP) (1–4).
cGAMP functions as a secondmessenger that binds to and acti-
vates the adaptor protein STING, which consists of a four-pass
transmembrane domain at the N terminus and a cytosolic
cGAMP-binding domain at the C terminus (5–8). Upon bind-
ing to cGAMP, inactive dimeric STING undergoes a conforma-
tional change, forms oligomers (9–11), and translocates from
the endoplasmic reticulum (ER) to the Golgi apparatus (12),
where STING is palmitoylated (13) and causes recruitment and
activation of the serine/threonine kinase TANK-binding kinase
1 (TBK1) (10). Activated TBK1 then phosphorylates the tran-
scription factor interferon regulatory factor 3 (IRF3) to induce
the expression of type I interferon (IFN) and chemokine genes
(14, 15). After activation at the Golgi, STING moves to endo-
somes and then to lysosomes, where STING is ubiquitinated and
recruits the autophagy receptor p62/sequestosome 1 (SQSTM1)
that leads to the degradation of STING to prevent the excessive
production of IFN (16–18). To understand themolecular mecha-
nisms of how the STING pathway is tightly regulated by mem-
brane trafficking, it is important to globally identify proteins that
spatiotemporally interact with STING in living cells.
BioID is a unique and powerful technique to identify transi-
ently or indirectly interacting proteins in living cells, and it is
based on the use of the biotin ligase BirA with promiscuous
R118G mutation (19). When a protein of interest fused to this
ligase is expressed in cells, it biotinylates lysine residues of
proximal proteins (20–22). The identification of biotinylated
proteins usually has been performed by pulldown with strepta-
vidin beads followed by LC-MS/MS analysis (23–25). However,
biotinylated peptides are rarely detected in this conventional
method because of the extremely high affinity of streptavidin
for biotin. As a result, mostly nonbiotinylated peptides are
identified, and they cannot be distinguished from peptides of
nonspecifically pull-downed contaminating proteins.
To overcome this problem, two groups have recently re-
ported an elegant approach using anti-biotin antibodies to
enrich and identify biotinylated peptides from proteolytic
digests of cellular proteins (26, 27). This new strategy enables
mapping of biotinylation sites on proteins and provides spatial
and topological information about proteins and protein com-
plexes. However, elution of biotinylated peptides from the anti-
bodies requires harsh conditions (e.g. TFA), which may increase
the contamination of nonbiotinylated peptides.
In this study, we have improved the BioID method to effi-
ciently and specifically enrich biotinylated peptides by using
Tamavidin 2-REV, an engineered avidin-like protein with re-
versible biotin-binding capability. Two avidin-like proteins,
Tamavidin 1 and Tamavidin 2, were previously isolated from
the Tamogitake mushroom (28), and one point mutation
(S36A) was introduced into Tamavidin 2 to break the hydrogen
bond between Tamavidin 2 and biotin (29). This engineered
Tamavidin 2, named Tamavidin 2-REV, reversibly bound to bi-
otinylated peptides, which could be mildly and specifically
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eluted by the addition of excess biotin. By using immobilized
Tamavidin 2-REV beads, over 4,000 biotinylated peptides were
identified and quantified from cells stably expressing STING
fused to TurboID (30). Whereas the biotinylation of various ER
proteins was detected in unstimulated cells, STING activation
caused the biotinylation of many proteins localized in the Golgi
and endosomes. These proteins included previously known and
unknown interactors of activated STING. The STING interac-
tome obtained in this study will provide new insights into the
STING signaling network, and our approach using Tamavidin
2-REV would enable researchers to utilize BioID and other
identification methods based on protein biotinylation more
easily and effectively.
Results
TurboID enables short-time biotin labeling of STING-proximal
proteins
Recently, Ting and coworkers developed TurboID, which
can catalyze proximity biotinylation with much greater effi-
ciency than the original BioID (30). To compare these biotin
ligase variants fused to STING in cells, the original BioID
(BirA*) fused to the C terminus or the N terminus of STING or
TurboID (BirA**) fused to the N terminus of STING (Fig. 1A)
was stably expressed in STING-null (SKO) RAW264.7 macro-
phages.When these cells were incubated with biotin for various
times, the biotinylation of many cellular proteins was quickly
and strongly detected by Western blotting in cells expressing
TurboID-STING (Fig. 1B). When DMXAA, a cell-permeable
artificial STING ligand (7, 31), was added to STING-null
RAW264.7 cells, phosphorylation of TBK1 was not detected
(Fig. 1C). However, DMXAA-induced phosphorylation of
TBK1was rescued by ectopic expression of either FLAG-tagged
STING or TurboID-STING (Fig. 1C), indicating that TurboID-
fused STING is functional. When TurboID-STING-expressing
cells were treated with or without DMXAA for 1 h in the pres-
ence of biotin, biotinylation of many proteins in both stimu-
lated and unstimulated cells was detected by Western blotting
(Fig. 1D). To observe TurboID-STING-mediated protein bioti-
nylation in situ, TurboID-STING-expressing cells were treated
with or without DMXAA for 1 h in the presence of biotin, fixed,
and stained with fluorescent streptavidin. In unstimulated cells,
both V5-tagged TurboID-STING and biotinylated proteins
exhibited a mesh-like distribution throughout the cytoplasm,
which is consistent with the ER localization of STING at the
steady state (Fig. 1E, left). On the other hand, DMXAA stimula-
tion caused the accumulation of both TurboID-STING and bi-
otinylated proteins in a Golgi-like perinuclear region, where
STING is known to translocate from the ER after its activation
(Fig. 1E, right). These results indicate that STING-fused Tur-
boID can quickly and strongly biotinylate STING-proximal
proteins in unstimulated and stimulated cells.
Specific enrichment of biotinylated peptides using Tamavidin
2-REV is useful for the BioID screen
An approach using anti-biotin antibodies for enrichment
and identification of biotinylated peptides has been developed
recently by two groups (26, 27). We reasoned that biotinylated
peptides could be more specifically and efficiently enriched by
Tamavidin 2-REV with reversible biotin-binding capability
(29). Total proteins from control or DMXAA-treated (for 1 h in
the presence of biotin in three biological replicates) TurboID-
STING-expressing cells were digested with trypsin, and biotin-
ylated peptides were directly captured on immobilized Tamavi-
din 2-REV beads without the cumbersome process of peptide
purification (Fig. 2A). Protease resistance of Tamavidin 2-REV
(29) is suited for direct incubation with digested peptide solu-
tions containing trypsin. The bound biotinylated peptides were
eluted with excess free biotin followed by LC-MS/MS and label-
free quantification. In total, we identified and quantified 5149
peptides, 4021 (78%) of which were biotinylated peptides (Fig. 2B,
Table S1). When biotinylated peptides in the same tryptic digests
were captured on anti-biotin antibody beads, LC-MS/MS analysis
of the eluates with TFA identified and quantified 11,534 peptides,
2795 (24%) of which were biotinylated peptides (Fig. 2B, Table
S2).Most (74%) of these biotinylated peptides were also identified
by enrichment with Tamavidin 2-REV (Fig. 2C). Thus, Tamavi-
din 2-REV enables large-scale identification of biotinylated pep-
tides fromBioID samples.
Quantification of biotinylated peptides of STING-proximal
proteins
We compared the Tamavidin 2-REV-enriched biotinylated
peptides between control and DMXAA-treated TurboID-
STING-expressing cells (Fig. 3A, Table S1). As expected, bioti-
nylation of TBK1 was significantly increased by DMXAA stimu-
lation (Fig. 3A). In addition, biotinylation of SQSTM1 was also
increased by DMXAA stimulation (Fig. 3A). Gene ontology anal-
ysis revealed that biotinylation of ER-related proteins was
decreased by DMXAA stimulation (Fig. 3B, left). On the other
hand, biotinylation of Golgi- and endosome-related proteins and
proteins involved in vesicle-mediated transport processes was
increased by DMXAA stimulation (Fig. 3B, right). These STING
interactome profiles are consistent with the activation-induced
STING trafficking, in which activated STING is transported from
the ER through theGolgi apparatus to endosomes (12, 18).
Interestingly, biotinylation of several putative ZDHHC-type
palmitoyl transferases (32) was increased by DMXAA stimula-
tion (Table S1). These ZDHHC proteins are known to be local-
ized in the Golgi (33) andmay be involved in the palmitoylation
of STING at the Golgi (13). As shown in Fig. S1, treatment with
the palmitoylation inhibitor 2-bromopalmitate (2-BP) sup-
pressed DMXAA-induced phosphorylation of TBK1 and IRF3
in RAW264.7 cells, as reported previously in other cell types
(13). This confirms the importance of palmitoylation in STING
signaling in RAW264.7macrophages.
Although STING is known to interact with IRF3 to promote
the TBK1-mediated phosphorylation of IRF3 (14, 15), biotiny-
lation of IRF3 was not detected in TurboID-STING-expressing
cells (Tables S1 and S2). In contrast, several biotinylated pep-
tides of IRF5 were significantly increased by DMXAA stimula-
tion (Fig. 3A). To examine whether STING activation causes
TBK1-mediated phosphorylation of IRF5, RAW264.7 cells
were treated with DMXAA in the presence or absence of the
TBK1 inhibitor BX795, and cell lysates were subjected to
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phosphate affinity (Phos-tag) SDS-PAGE (34), followed by
Western blotting with anti-IRF5 antibody. As shown in Fig. 4A,
DMXAA stimulation induced an electrophoretic mobility shift
of IRF5. This mobility shift was reversed by treatment of the
cell lysates with lambda protein phosphatase (Fig. 4B), confirm-
ing that the shift is caused by phosphorylation. Furthermore,
the DMXAA-induced shift of IRF5 was blocked by pretreat-
ment with BX795 (Fig. 4C), indicating that IRF5 is phosphory-
lated by the STING-TBK1 pathway.
IFITM3 interacts with STING at the late activation stage
Among the newly identified STING-proximal proteins, we
focused on IFITM3 because of its important role in antiviral
defense (35–38). DMXAA stimulation induced biotinylation of
IFITM3 at K24 in the N-terminal region and K88 in the middle
region (Figs. 3A and 5A). Although early studies reported
IFITM3 as a two-pass transmembrane protein with luminal N
and C termini, recent studies have proposed a new topology
with a cytosolic N terminus and a luminal C terminus (39, 40).
Because STING-fused TurboID localizes to the cytosol (Fig.
1A), biotinylation of IFITM3 in the N-terminal region supports
the latter topologymodel.
To observe the trafficking-dependent association between
STING and IFITM3, we established RAW264.7 cells stably
expressing GFP-fused STING and analyzed colocalization of
GFP-STING with IFITM3. Endogenous IFITM3 was localized
to an endolysosome-like perinuclear region (36) regardless of
STING activation status and did not colocalize with GFP-
STING at the steady state (Fig. 5B). UponDMXAA stimulation,
GFP-STING was accumulated in the IFITM3-positive com-
partments (Fig. 5B, arrows). It should be noted that DMXAA
also induced the formation of STING aggregates, possibly
SQSTM1-positive compartments (17, 18), where IFITM3 was
hardly detected (Fig. 5B, arrowheads). To further examine the
interaction between STING and IFITM3, lysates from GFP-
STING-expressing cells were immunoprecipitated with anti-
GFP nanobody-coupled beads, followed by Western blotting
with anti-IFITM3 antibody. The interaction between STING
and IFITM3 was gradually increased from 1 to 4 h after
DMXAA stimulation (Fig. 5, C and D). In contrast, DMXAA
stimulation induced phosphorylation of TBK1 at 1 h, and this
phosphorylation was diminished by 4 h (Fig. 5C). IFITM3 was
also coimmunoprecipitated with endogenous STING from
lysates of DMXAA-stimulated RAW264.7 cells (Fig. 5E). The
amount of coimmunoprecipitated IFITM3 was increased at 4 h
after DMXAA stimulation, although endogenous STING pro-
tein was strongly reduced at 4 h (Fig. 5E). These results define
IFITM3 as a novel STING interactor at the late activation stage.
Discussion
In this study, we have developed a simple and easy method
for enrichment and identification of biotinylated peptides using
Tamavidin 2-REV. To date, other avidin- or streptavidin-
derived artificial proteins that were designed to bind biotin
Figure 1. Biotin labeling of STING-proximal proteins. A, schematic of the BioID and TurboID fusion proteins. B, STING-null (SKO) RAW264.7 cells expressing
STING-BioID, BioID-STING, or TurboID-STING were cultured in the presence of 500mM biotin for the indicated times. The cell lysates were analyzed byWestern
blotting with HRP-conjugated streptavidin and antibodies to STING and a-tubulin. C, WT RAW264.7 cells, STING-null RAW264.7 cells, or STING-null RAW264.7
cells expressing either STING-FLAG or TurboID-STING were treated with 30 mg/ml DMXAA for the indicated times. The cell lysates were analyzed by Western
blotting with antibodies to STING, phospho-TBK1, and a-tubulin. D, TurboID-STING-expressing cells were treated with DMSO (2) or 30 mg/ml DMXAA for 1 h
in the presence or absence of 500 mM biotin. The cell lysates were analyzed by Western blotting with HRP-conjugated streptavidin and antibodies to STING
and a-tubulin. E, TurboID-STING-expressing cells were treated with DMSO or 100 mg/ml DMXAA for 1 h in the presence of biotin, fixed, and stained with
DyLight 488-conjugated streptavidin, anti-V5 antibody, and DAPI, followed by observation under a confocal microscope. Scale bar, 5mm.
Figure 2. Comparison of Tamavidin 2-REV-based enrichment and antibody-based enrichment for identification of biotinylated peptides. A, sche-
matic workflow of enrichment and identification of biotinylated peptides using Tamavidin 2-REV, which has reversible biotin-binding capability. Three biologi-
cal replicates for each sample were analyzed by LC-MS/MS analysis. B, the number of total peptides and biotinylated peptides that were identified and
quantified by LC-MS/MS analysis. C, overlap of biotinylated peptides identified and quantified using Tamavidin 2-REV-based enrichment or anti-biotin anti-
body-based enrichment.
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reversibly have been reported (29), such as nitro-avidin (41),
streptavidn-S45A (42), and streptavidin-M4 (43). However,
Tamavidin 2-REV has several advantages over these other pro-
teins for enrichment and MS-based identification of biotinyl-
ated peptides. First, protease resistance of Tamavidin 2-REV is
suited for direct incubation with digested peptides containing
proteases, such as trypsin, without peptide purification. Sec-
ond, the neutral pI (pI 7.4) of Tamavidin 2-REV is expected to
reduce charge-derived nonspecific binding. Third, Tamavidin
2-REV can be highly expressed as a soluble protein in E. coli
and does not tend to aggregate.
Enrichment of biotinylated peptides from complex peptide
mixtures greatly increases identification of biotinylation sites
compared with streptavidin-based enrichment of biotinylated
proteins (26, 27). Tamavidin 2-REV-based enrichment of bio-
tinylated peptides is a time- and cost-effective method com-
pared with antibody-based enrichment. Whereas elution of bi-
otinylated peptides from anti-biotin antibodies requires harsh
conditions, biotinylated peptides can be specifically eluted
from Tamavidin 2-REV by adding excess free biotin under mild
conditions. In fact, enrichment efficiency using Tamavidin 2-
REVwas over 3-fold higher than that using anti-biotin antibody
(Fig. 2B), which may have another disadvantage of lot-to-lot
variation. Thus, enrichment of biotinylated peptides using
Tamavidin 2-REV followed by identification of biotinylation
sites by LC-MS/MSwould be useful for a wide range of applica-
tions that require biotinylation of proteins. These applications
Figure 3. Activation-induced changes in STING-proximal proteins. A, volcano plot showing differential peptide profiles in DMSO- and DMXAA (30mg/ml)-
treated TurboID-STING-expressing cells. Identified and quantified biotinylated peptides are plotted as log2 fold change (DMXAA/DMSO) versus negative log10
of the t test q value. Biotinylated peptides of known interactors of activated STING and STING itself are shown in blue, and those of unknown STING interactors
are shown in red. B, enrichment analysis of the ontology for proteins of biotinylated peptides that decreased (left) or increased (right) after DMXAA stimulation.
Figure 4. IRF5 is phosphorylated by TBK1 upon STING activation. IRF5
phosphorylation in cell lysates was analyzed by Phos-tag Western blotting
with anti-IRF5 antibody. A, RAW264.7 cells were stimulated with 30 mg/ml
DMXAA for the indicated times. B, RAW264.7 cells were treated with DMSO
(2) or 30 mg/ml DMXAA for 1 h. The cell lysates were incubated with or with-
out l protein phosphatase (l-PPase) before Western blotting. C, RAW264.7
cells were pretreated with or without 1mM BX795 for 30min and then treated
with DMSO or 30 mg/ml DMXAA for 1 h. Representative data are shown from
three (A) or two (B and C) independent experiments.
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include proximity labeling (BioID and APEX [44]), cell surface
labeling, cross-linking MS (45), and mapping sites of posttrans-
lational modifications (PTMs), such as palmitoylation (46), S-
nitrosylation, sulfenylation, andO-GlcNAcmodification (27).
It is well known that IRF3 is the major transcription factor
downstream of the STING-TBK1 pathway. Although the rea-
son why biotinylation of IRF5 but not IRF3 was detected is
unclear, it may be because of markedly higher expression of
IRF5 protein in RAW264.7 cells than other cell lines tested (Fig.
S2). Whereas S396 of IRF3 is phosphorylated by TBK1 to
induce its nuclear translocation and gene expression, S462 of
IRF5, a position equivalent to that of S396 of IRF3, is not phos-
phorylated by TBK1 but is phosphorylated by IKKb (47, 48).
Detailed mechanisms and functions of the STING-TBK1-
mediated phosphorylation of IRF5 remain to be elucidated in
the future.
In the BioID screen using TurboID-fused STING, we identi-
fied the endolysosomal antiviral protein IFITM3 as a novel
STING interactor. Because IFITM3 has been reported to have
redundant functions with IFITM1 and IFITM2 (35, 38, 39), we
generated triple knockout (TKO) RAW264.7 cells lacking
IFITM1, IFITM2, and IFITM3 (Fig. S3A). However, the TKO
cells andWT cells exhibited similar kinetics of phosphorylation
of TBK1 and degradation of STING after DMXAA stimulation
(Fig. S3B). Although the physiological role of the STING–
IFITM3 interaction remains unclear, STING showed increased
binding to IFITM3 concomitant with decreased phosphoryla-
tion of TBK1 at the late activation stage (Fig. 5, C and E), sug-
gesting that TBK1 and IFITM3 have different roles in STING
signaling. IFITM3 is an antiviral restriction factor especially
against enveloped RNA viruses, including influenza A virus,
West Nile virus, dengue virus, and Zika virus (35–38). Whereas
STING is known to be essential for IFN response against DNA
viruses, accumulating evidence suggests that STING also
restricts the replication of such RNA viruses through undefined
mechanisms (49–52). Thus, STINGmight regulate the antiviral
activity of IFITM3. Future studies need to clarify the role of the
STING-IFITM3 axis on antiviral immune responses.
Figure 5. Activation-induced interaction between STING and IFITM3. A, protein structure and topology of IFITM3 with biotinylation sites are shown. TM,
transmembrane domain. B, RAW264.7 cells expressing GFP-STING (RAW/GFP-STING cells) were treated with DMSO or 100 mg/ml DMXAA for 4 h. The cells
were fixed and stained with anti-IFITM3 antibody and DAPI, followed by observation under a confocal microscope. Scale bar, 5 mm. C, RAW/GFP-STING cells
were treated with 30 mg/ml DMXAA for the indicated times. The cells were lysed and immunoprecipitated with anti-Spot tag nanobody-coupled magnetic
agarose beads (Spot-Trap_MA, control) or anti-GFP nanobody-coupledmagnetic agarose beads (GFP-Trap_MA), followed byWestern blottingwith antibodies
to IFITM3, GFP, and phospho-TBK1.D, the band intensities of IFITM3 immunoprecipitated with GFP-Trap_MAwere quantified using the Image Laboratory soft-
ware (n = 3). A scatter plot with the mean value line is shown. E, RAW264.7 cells were treated with or without 30 mg/ml DMXAA for the indicated times. The
cells were lysed and immunoprecipitated with anti-STING antibody, followed by Western blotting with antibodies to IFITM3 and STING. Representative data
are shown from two (B and E) or three (C) independent experiments.
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Experimental procedures
Reagents and antibodies
MagCapture HP Tamavidin 2-REV magnetic beads and 2-
bromohexadecanoic acid (2-BP) were purchased from FUJI-
FILM Wako Pure Chemical (Osaka, Japan). HRP-conjugated
streptavidin and DyLight 488-conjugated streptavidin were
purchased from BioLegend (San Diego, CA). Anti-V5 mAb
(M215-3) and anti-GFP pAb (598) were from MBL (Nagoya,
Japan). Anti-IFITM3 pAb (ab15592) and anti-IRF5 mAb
(ab181553) were from Abcam (Cambridge, United Kingdom).
The PTMScan anti-biotin kit (41343), anti-STING mAb (13647),
and anti-phospho-TBK1 (Ser172)mAb (5483) were fromCell Sig-
naling Technology (Danvers, MA). GFP-Trap_MA and Spot-
Trap_MA (for immunoprecipitation) were from ChromoTek
(Planegg-Martinsried, Germany). DMXAA was from Ark Pharm,
Inc. (Arlington Heights, IL). D-biotin was from Nacalai Tesque
(Kyoto, Japan).
Cell lines
RAW264.7 murine macrophage cells were cultured in DMEM
containing 10% FCS. STING-deficient RAW264.7 cells and
the STING-deficient cells stably expressing FLAG-tagged
STING were generated previously (53). To generate cells
expressing TurboID-STING fusion protein, V5-TurboID
(Addgene) followed by 23 GGGGS flexible linker was fused
to the N terminus of mouse STING. Classical BioID was also
fused to the N terminus or C terminus of mouse STING,
inserting the linker between them. These fusion constructs
were stably introduced into the STING-deficient RAW264.7
cells using the PiggyBac transposon vector (54) kindly gifted
by Dr. Yasuhide Ohinata (Chiba University). After puromycin
treatment, the bulk of the resistant cells was used in this
study. To generate cells expressing GFP-STING fusion pro-
tein, EGFP followed by 23 GGGGS linker was fused to the
N terminus of mouse STING and introduced into the pEF-
BOS vector. After transfection by electroporation using the
NEPA21 system (Nepagene, Chiba, Japan), a single clone was
obtained by limiting dilution. To generate IFITM1/2/3 TKO
cells, the px330 vector (Addgene) expressing Cas9 and single
guide RNA targeting for mouse IFITM1, IFITM2, and
IFITM3 (59-AGGGACCAGACCACATGGTC-39) and EGFP
expression vector were cotransfected into RAW264.7 cells by
electroporation using the NEPA21 system. After 48 h of incu-
bation at 37 °C, the cells strongly expressing EGFP were
sorted by an S3e Cell Sorter (Bio-Rad, Hercules, CA) and sub-
jected to limiting dilution, and the mutated clones were iden-
tified byWestern blotting and DNA sequencing.
Preparation of cell lysates and immunoprecipitates
For preparing total cell lysates, cells were directly lysed in 13
SDS sample buffer (40 mM Tris-HCl [pH 6.8], 2% SDS, 5% glyc-
erol, 1% b-mercaptoethanol, and 0.01% bromphenol blue) and
heated at 95 °C for 10min. For immunoprecipitation assay, cells
were lysed in NP-40 lysis buffer (20 mM Tris-HCl [pH 7.5], 150
mM NaCl, 1 mM EDTA, 1% NP-40, and 10% glycerol) supple-
mented with a protease inhibitor mixture (Nacalai Tesque), a
phosphatase inhibitor mixture (Nacalai Tesque), and 50 units/
ml Benzonase nuclease (MerckMillipore, Burlington, MA). Af-
ter incubation on ice for 10 min, the lysates were centrifuged at
20,0003 g for 15 min at 4 °C. The supernatants were incubated
with Spot-Trap_MA, GFP-Trap_MA, or anti-STING antibody-
coupled Protein GMag-Sepharose (GE Healthcare, Little Chal-
font, United Kingdom) at 4 °C for 3 h. After washing with the
NP-40 lysis buffer four times, the beads were resuspended in
13 SDS sample buffer and heated at 95 °C for 10min.
SDS-PAGE and Western blotting
Total cell lysates and immunoprecipitates were separated by
electrophoresis on a 10% or 16% (for IFITM3) polyacrylamide
gel and transferred onto a PVDF membrane (MerckMillipore).
After blocking, the membrane was incubated with primary
antibodies in 5% skim milk overnight at 4 °C, followed by incu-
bation with HRP-conjugated secondary antibodies. Protein
bands on the membrane were detected by a ChemiDoc Touch
Imaging System (Bio-Rad) after incubation of the membrane
with Clarity Western ECL substrate (Bio-Rad) or ImmunoStar
LD (FUJIFILM Wako). For Phos-tag Western blotting, cells
were lysed in 6 M guanidine-HCl containing 100 mM HEPES-
NaOH (pH 7.5) and 2 mM DTT, followed by protein precipita-
tion using a PAGE Clean-up kit (Nacalai Tesque). After dissolv-
ing in 13 SDS sample buffer, SDS-PAGE was performed using
a gel containing 25 mM Phos-tag acrylamide (FUJIFILM Wako)
and 50mMMnCl2 as described previously (55). For treatment with
lambda protein phosphatase (l-PPase), cell lysates were concen-
trated and buffer exchanged into 13 NEB l-PPase buffer (New
England Biolabs, Ipswich, MA) using Amicon Ultra 30K (Merck
Millipore). The samples were incubated with 4000 units/ml
l-PPase (New England Biolabs) in the presence of 1 mM MnCl2
for 30 min at 30 °C. All Western blotting experiments were
repeated at least twice, and representative images are shown.
Immunostaining
Cells were seeded on coverslips in a 12-well plate. After treat-
ment with DMSO or DMXAA, the cells were fixed with 3.7%
formaldehyde–PBS for 15 min at 37 °C and permeabilized with
0.2% Triton X-100–PBS for 10 min at room temperature. The
coverslips were incubated with primary antibodies in 2% goat
serum–PBS for 1 h at 37 °C. After washing with PBS three
times, the coverslips were incubated with Alexa Fluor-conju-
gated secondarily antibodies and 49,6-diamidino-2-phenylin-
dole dihydrochloride (DAPI) for 1 h at room temperature in
the dark. After washing with PBS three times and subsequent
rinse with distilled water, the coverslips were mounted on the
glass slides with FluorSave reagent (Merck Millipore). The im-
munofluorescence images were obtained by an FV1200 confo-
cal laser scanningmicroscope (Olympus, Tokyo, Japan). All im-
munostaining experiments were repeated at least twice, and
representative images are shown.
Sample preparation for the BioID screen
The STING-null RAW264.7 cells expressing TurboID-
STING were seeded in 15-cm dishes and cultured overnight.
The cells were treated with DMSO or 30 mg/ml DMXAA, and
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biotin (final concentration of 500 mM) was added to the me-
dium. After 1 h of incubation, the cells were washed with
HEPES-buffered saline twice and lysed in 6 M guanidine-HCl
containing 100 mM HEPES-NaOH (pH 7.5), 10 mM Tris (2-car-
boxyethyl) phosphine, and 40 mM chloroacetamide. The lysates
were dissolved by heating and sonication and then centrifuged
at 20,0003 g for 15 min at 4 °C. The supernatants were recov-
ered, and proteins (3.4 mg each) were purified by methanol–
chloroform precipitation and solubilized by 0.1% RapiGest SF
(Waters, Milford, MA) in 50 mM triethylammonium bicarbon-
ate. After repeated sonication and vortexing, the proteins were
digested with 34 mg trypsin (MS grade, Thermo Fisher Scien-
tific, Waltham, MA) at 37 °C overnight. The resultant peptide
solutions were diluted 5-fold with TBS (50 mM Tris-HCl [pH
7.5] and 150mMNaCl) and divided in half for enrichment using
Tamavidin 2-REV or anti-biotin antibody.
Enrichment of biotinylated peptides using Tamavidin 2-REV
Biotinylated peptides from the BioID samples were captured
on 15 ml slurry of MagCapture HP Tamavidin 2-REV magnetic
beads in the presence of 1 mg/ml Pefabloc SC (Sigma-Aldrich)
during 3 h of incubation at 4 °C. After washing with TBS five
times, the biotinylated peptides were eluted with 100 ml of 1 mM
biotin in TBS for 15 min at 95 °C twice. The combined eluates
were desalted using GL-Tip SDB (GL Sciences, Tokyo, Japan),
evaporated in a SpeedVac concentrator (Thermo Fisher Scien-
tific), and redissolved in 0.1%TFA and 3% acetonitrile (ACN).
Enrichment of biotinylated peptides using anti-biotin antibody
Biotinylated peptides from the BioID samples were captured
on 20 ml slurry of the anti-biotin (A7C2A) rabbit mAb-conju-
gated beads (41343, Cell Signaling Technology) in the presence
of 1 mg/ml Pefabloc SC during 3 h of incubation at 4 °C. After
washing with TBS four times and with ultrapure water twice,
the biotinylated peptides were eluted with 100 ml of 0.2% TFA
in 80% ACN for 10 min at room temperature twice. The com-
bined eluates were evaporated, dissolved in 0.1% TFA, and
desalted using GL-Tip SDB. The desalted eluates were further
evaporated and redissolved in 0.1% TFA and 3%ACN.
Data-dependent LC-MS/MS analysis
LC-MS/MS analysis of the resultant peptides was performed
on an EASY-nLC 1200 UHPLC connected to a Q Exactive Plus
mass spectrometer through a nanoelectrospray ion source
(Thermo Fisher Scientific). The peptides were separated on a
75-mm-inner-diameter, 150-mm C18 reversed-phase column
(Nikkyo Technos, Tokyo, Japan) with a linear 4–32% ACN gra-
dient for 0–60 min, followed by an increase to 80% ACN for 10
min. The mass spectrometer was operated in data-dependent
acquisition mode with a top 10 MS/MS method. MS1 spectra
were measured with a resolution of 70,000, an AGC target of 13
106, and a mass range from 350 to 1,500 m/z. MS/MS spectra
were triggered at a resolution of 17,500, an AGC target of 5 3
104, an isolation window of 2.0m/z, a maximum injection time of
200 ms, and a normalized collision energy of 27. Dynamic exclu-
sion was set to 15 s. Raw data were directly analyzed against the
Swiss-Prot database, version 2017-10-25, restricted toMus mus-
culus (25,097 sequences) using Proteome Discoverer version 2.4
(Thermo Fisher Scientific) with the Sequest HT search engine.
The search parameters were the following: (a) trypsin as an
enzyme with up to two missed cleavages; (b) precursor mass tol-
erance of 10 ppm; (c) fragmentmass tolerance of 0.02 Da; (d) car-
bamidomethylation of cysteine as a fixed modification; and (e)
acetylation of protein N terminus, oxidation of methionine, and
biotinylation of lysine as variable modifications. Peptides were fil-
tered at a false discovery rate (FDR) of 1% using the Percolator
node of Proteome Discoverer. Label-free quantification was per-
formed based on intensities of precursor ions using the Precursor
Ions Quantifier node. Normalization was performed such that
the total sum of abundance values for each sample over all pep-
tides was the same. The data were analyzed by a two-tailed Stu-
dent’s t test, and the resulting p values were adjusted using the
Benjamini-Hochbergmethod for controlling the FDR (56). A vol-
cano plot was used for showing the mean fold change and q value
(FDR-adjusted p value) of each biotinylated peptide.
Gene ontology enrichment analysis
The lists of proteins of differentially biotinylated peptides
before and after STING activation in the BioID screen (fold
change of .2, q value of ,0.05) were analyzed using DAVID
Bioinformatics Resources version 6.8 (count threshold, .4;
Benjamin-corrected p value,,0.05). Top 10 enriched gene on-
tology terms of cellular components are shown.
Data availability
The MS proteomics data have been deposited in the Proteo-
meXchange Consortium via the jPOST partner repository with
the data set identifiers PXD018802 and PXD018803 (57).
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